Gantenerumab

From Wikipedia, the free encyclopedia
Gantenerumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target Beta-amyloid (Aβ40/42)
Clinical data
Legal status ?
Identifiers
CAS number 89957-37-9 N
ATC code None
UNII 4DF060P933 YesY
KEGG D09680 YesY
Chemical data
Formula C6496H10072N1740O2024S42 
Mol. mass 146.3 kDa (peptide)
 N (what is this?)  (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]

Gantenerumab is currently being evaluated in a prodromal Alzheimer's Disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. [4]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
  2. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  3. ↑ ClinicalTrials.gov NCT00531804 A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease
  4. ↑ http://www.scarletroadstudy.com/en-CA/index.aspx
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Mouse ("-ciro-")
Chimeric ("-cixi-")
Humanized ("-cizu-")
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Humanized ("-nezu-"/"-neuzu-")
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.